(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch - 2Medical team successfully delivers baby and removes massive tumor
- 3The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 4A definitive Cruiser Standoff: Decision in favor of Your #1 Ride
- 5'Supergirl' drops 1st teaser trailer: Watch Milly Alcock as Kara Zor-El and the return of Krypto the Superdog
- Compassion and Association: Building Significant Connections
- Most loved Fish Dish: What's Your Sea Pleasure?
- Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- Nvidia Share Price Could Be Hit Hard By Iran War
- Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues
- Help Your Efficiency: 10 Authoritative Apparatuses to Attempt
- 'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
- 5 Wellbeing Applications Assist You With remaining Fit
